Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | PARP1 | P09874 | 8/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.45 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30098446 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TDP1PARP1KDM4ELMNA | |
| SCHEMBL57166 | 0.80 | TDP1 (1.00) | ALDH1A1TDP1PARP1CYP3A4HSD17B10 | |
| SCHEMBL29475175 | 0.80 | TDP1 (1.00) | ALDH1A1TDP1PARP1CYP3A4HSD17B10 | |
| SCHEMBL16099065 | 0.80 | ALDH1A1 (0.65) | ALDH1A1TDP1PARP1KDM4ELMNA | |
| SCHEMBL28093598 | 0.78 | TDP1 (0.95) | ALDH1A1TDP1PARP1CYP3A4HSD17B10 | |
| SCHEMBL15717048 | 0.78 | ALDH1A1 (0.64) | ALDH1A1TDP1PARP1KDM4EPOLB | |
| SCHEMBL29471420 | 0.78 | ALDH1A1 (0.64) | ALDH1A1TDP1PARP1KDM4ECYP1A2 | |
| SCHEMBL28549 | 0.78 | ALDH1A1 (0.64) | ALDH1A1TDP1PARP1KDM4ECYP1A2 | |
| SCHEMBL22120275 | 0.76 | ALDH1A1 (0.61) | ALDH1A1TDP1PARP1KDM4ELMNA | |
| SCHEMBL487276 | 0.75 | ALDH1A1 (0.59) | ALDH1A1TDP1PARP1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1998051307-A1 | METHODS FOR TREATING INFLAMMATION, INFLAMMATORY DISEASES, ARTHRITIS AND STROKE USING pADPRT INHIBITORS | OCTAMER, INC. (US) | 1998-11-19 | — | — | WO | claimed |
| US-12590066-B2 | Fused-heterocyclyl-carbonohydrazonoyl dicyanide compounds and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-31 | — | — | US | disclosed |
| US-20230295095-A1 | NOVEL FUSED-HETEROCYCLYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-09-21 | — | — | US | disclosed |
| EP-4169905-A1 | NOVEL FUSED HETEROCYCLIC CARBONOHYDRAZONOYL DICYANIDE COMPOUND AND USE THEREOF | Korea Institute of Science and Technology (KR) | 2023-04-26 | — | — | EP | disclosed |
| CN-115867277-A | Novel fused heterocyclyl-carbohydrazone acyldinitrile compounds and use thereof | 韩国科学技术研究院 | 2023-03-28 | — | — | CN | disclosed |
| CN-115427394-A | Heterocyclic compounds for modulating NR2F6 | TES制药有限责任公司 | 2022-12-02 | — | — | CN | disclosed |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| WO-2021256899-A1 | NOVEL FUSED HETEROCYCLIC CARBONOHYDRAZONOYL DICYANIDE COMPOUND AND USE THEREOF | 한국과학기술연구원 | 2021-12-23 | — | — | WO | disclosed |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S R L (IT) | 2021-10-21 | — | — | US | disclosed |
| CN-106588765-A | Method for hydroxylation of nitrogen oxide C2-position | 天津科技大学 | 2017-04-26 | — | — | CN | disclosed |
| US-20040116694-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2004-06-17 | — | — | US | disclosed |
| WO-2003082827-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-09 | — | — | WO | disclosed |
| US-5877185-A | THERAPY FOR CANCER OR RETROVIRUS | OCTAMER, INC. (US) | 1999-03-02 | — | — | US | disclosed |
| US-5670518-A | ANTITUMOR AGENTS; VIRICIDES | OCTAMER, INC. | 1997-09-23 | — | — | US | disclosed |
| WO-1996022791-A9 | NOVEL SYNERGISTIC COMPOSITIONS USEFUL AS ANTI-TUMOR OR ANTI-RETROVIRAL AGENTS | — | 1996-10-03 | — | — | WO | disclosed |
| WO-1996022791-A1 | NOVEL SYNERGISTIC COMPOSITIONS USEFUL AS ANTI-TUMOR OR ANTI-RETROVIRAL AGENTS | OCTAMER, INC. (US) | 1996-08-01 | — | — | WO | disclosed |
| EP-0355750-B1 | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process | WARNER LAMBERT CO (US) | 1995-01-25 | — | — | EP | disclosed |
| US-5262564-A | Anticarcinogenic agents | OCTAMER, INC. (US) | 1993-11-16 | — | — | US | disclosed |
| US-5177075-A | Antitumor agents | WARNER-LAMBERT COMPANY (US) | 1993-01-05 | — | — | US | disclosed |
| EP-0355750-A1 | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process | WARNER-LAMBERT COMPANY (US) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | ALDH1A1 2328/4885TDP1 2327/4885PARP1 3135/4885 |
| US-12590066-B2 | Fused-heterocyclyl-carbonohydrazonoyl dicyanide compounds and use thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, CLIC1 | ALDH1A1 592/4885TDP1 2103/4885PARP1 2414/4885 |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | ALDH1A1 2328/4885TDP1 2327/4885PARP1 3135/4885 |
| US-20230295095-A1 | NOVEL FUSED-HETEROCYCLYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS AND USE THEREOF | CBR3, DBF4, DDT | ALDH1A1 1343/4885TDP1 2868/4885PARP1 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.